Bio-Rad Laboratories, Inc. (BIO) reported the launch of the BioPlex 2200 25-OH Vitamin D kit, which will be used in the company's BioPlex 2200 system. For now, the company has launched the kit only in the international market.
The assay provides a fully-automated method for the quantitative measurement of total 25-hydroxy vitamin D in human serum. The 25-hydroxy vitamin D test is the most accurate way to determine the amount of vitamin D present in an individual's body.
A Brief Note about Vitamin D Testing
Vitamin D, a fat-soluble organic component that promotes absorption and metabolism of calcium and phosphorus in one's body, plays a crucial role in maintaining one's bone health. Recently, a number of studies validated associations between Vitamin D deficiency and an increased risk of cardiovascular disease, autoimmune disease, and cancer.
As a result, physicians nowadays include Vitamin D testing as part of the routine assessment of their patients' overall health. This has led to substantial growth in the Vitamin D testing market, over the past several years.
Per management at Bio-Rad, the aforementioned Vitamin D kit has the potential to amplify the company's portfolio of autoimmune and infectious disease analyses.
What is BioPlex 2200 System?
Bio-Rad's BioPlex 2200 system is the first and only fully-automated, random access multiplex testing system used for clinical diagnostic analyses that enables the detection and quantification of multiple analytes – proteins and peptides, or nucleic acids – in a single sample volume.
This system provides clinical laboratories with the capability to rapidly process multiple individual tests that are traditionally processed separately. The Bio-Plex multiplex system can multiplex up to 500 different tests simultaneously.
Bio-Rad currently has a Zacks Rank #5 (Sell). Some better-ranked medical product stocks that warrant a look are OraSure Technologies, Inc. (OSUR), Cardica Inc. (CRDC), and ICU Medical, Inc. (ICUI). While OraSure sports a Zacks Rank #1 (Strong Buy), Cardica and ICU Medical hold a Zacks Rank #2 (Buy).